Nymox Pharmaceutical Corporation
Hedge Funds Holdings
Last updated:
Nymox Pharmaceutical Corporation‘s stocks are currently a part of 22 hedge funds’ portfolios, which represents 0.64% of the total amount of its stocks outstanding. This makes up a total of 570.53K shares of Nymox Pharmaceutical Corporation. Compared to the previous quarter, the number fell by -44.43% or -456.09K shares fewer. As for the holding position changes, 18.18% (4) of current hedge fund investors increased the number of shares held, 22.73% (5) of current holders sold a part of the shares held, and 13.64% (3) closed the holdings completely. 1 hedge funds are new holders of Nymox Pharmaceutical Corporation stock in Q1 2023, it is 4.55% of total holders.
Hedge funds holding Nymox Pharmaceutical (Q2 2018 – Q1 2023)
| Q2 2018 | 48 |
|---|---|
| Q3 2018 | 45 |
| Q4 2018 | 45 |
| Q1 2019 | 44 |
| Q2 2019 | 38 |
| Q3 2019 | 36 |
| Q4 2019 | 44 |
| Q1 2020 | 46 |
| Q2 2020 | 62 |
| Q3 2020 | 62 |
| Q4 2020 | 54 |
| Q1 2021 | 55 |
| Q2 2021 | 47 |
| Q3 2021 | 35 |
| Q4 2021 | 37 |
| Q1 2022 | 34 |
| Q2 2022 | 32 |
| Q3 2022 | 27 |
| Q4 2022 | 35 |
| Q1 2023 | 22 |
Hedge funds changes in Nymox Pharmaceutical positions (Q2 2018 – Q1 2023)
| Q2 2018 | 3 | 23 | 5 | 2 | 15 |
|---|---|---|---|---|---|
| Q3 2018 | 1 | 18 | 11 | 4 | 11 |
| Q4 2018 | 3 | 11 | 16 | 3 | 12 |
| Q1 2019 | 3 | 11 | 17 | 4 | 9 |
| Q2 2019 | 8 | 5 | 13 | 14 | -2 |
| Q3 2019 | 5 | 3 | 13 | 7 | 8 |
| Q4 2019 | 11 | 8 | 10 | 3 | 12 |
| Q1 2020 | 12 | 9 | 8 | 8 | 9 |
| Q2 2020 | 23 | 13 | 10 | 8 | 8 |
| Q3 2020 | 7 | 14 | 22 | 7 | 12 |
| Q4 2020 | 2 | 21 | 13 | 10 | 8 |
| Q1 2021 | 4 | 20 | 12 | 3 | 16 |
| Q2 2021 | 13 | 11 | 12 | 21 | -10 |
| Q3 2021 | 1 | 6 | 14 | 12 | 2 |
| Q4 2021 | 6 | 5 | 15 | 4 | 7 |
| Q1 2022 | 8 | 3 | 6 | 11 | 6 |
| Q2 2022 | 6 | 1 | 9 | 8 | 8 |
| Q3 2022 | 6 | 4 | 6 | 11 | 0 |
| Q4 2022 | 10 | 6 | 7 | 2 | 10 |
| Q1 2023 | 1 | 4 | 5 | 3 | 9 |
Hedge funds changes in Nymox Pharmaceutical stock options (Q2 2018 – Q1 2023)
| Q2 2018 | 492,000 | 2,888,000 |
|---|---|---|
| Q3 2018 | 113,000 | 1,712,000 |
| Q4 2018 | 123,000 | 300,000 |
| Q1 2019 | 90,000 | 112,000 |
| Q2 2019 | 80,000 | 77,000 |
| Q3 2019 | 69,000 | 61,000 |
| Q4 2019 | 27,000 | 40,000 |
| Q1 2020 | 99,000 | 113,000 |
| Q2 2020 | 621,000 | 68,000 |
| Q3 2020 | 55,000 | 99,000 |
| Q4 2020 | 27,000 | 84,000 |
| Q1 2021 | 45,000 | 13,000 |
| Q2 2021 | 60,000 | 20,000 |
| Q3 2021 | 74,000 | 38,000 |
| Q4 2021 | 12,000 | 12,000 |
| Q1 2022 | 35,000 | 37,000 |
| Q2 2022 | 1,000 | 10,000 |
| Q3 2022 | 7,000 | 9,000 |
| Q4 2022 | 15,792 | 2,435 |
| Q1 2023 | 0 | 2,788,000 |